Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Dec;41(12):2602–2605. doi: 10.1128/aac.41.12.2602

Appearance of a metronidazole-resistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole-resistant and -sensitive strains.

S Matsumoto 1, Y Washizuka 1, Y Matsumoto 1, S Tawara 1, F Ikeda 1, Y Yokota 1, M Karita 1
PMCID: PMC164176  PMID: 9420026

Abstract

We tested whether antibiotic-resistant strains appeared in vivo after the failure of treatment using the Helicobacter pylori-infected euthymic mouse model. The numbers of colonies isolated from 56 ICR mice 2 weeks after 4 days of treatment with metronidazole (3.2, 10, or 32 mg/kg of body weight) or amoxicillin (1, 3.2 or 10 mg/kg), with treatment started 4 days after H. pylori CPY2052 inoculation, were counted, and the isolated strains were tested for their sensitivities to two antibiotics to rule out the presence of antibiotic-resistant strains. One metronidazole-resistant strain was detected in a mouse treated with 10 mg of metronidazole per kg, and the MIC of metronidazole for this strain was 25 microg/ml, compared to a MIC of 1.56 microg/ml for the original strain. However, no resistant strain was detected in the amoxicillin treatment group. After the examination described above, mice challenged with a metronidazole-resistant or -sensitive strain isolated from the stomach of a mouse were treated with metronidazole or amoxicillin. The metronidazole-resistant strain was more difficult to eradicate in vivo than the sensitive strain after treatment with metronidazole but not after treatment with amoxicillin. Thus, a metronidazole-resistant H. pylori strain was selected by insufficient treatment, but no resistant strain was selected with amoxicillin. Eradication of a metronidazole-resistant H. pylori strain in vivo required a higher dosage than eradication of a metronidazole-sensitive H. pylori strain. These results may explain one of the reasons for H. pylori treatment failure.

Full Text

The Full Text of this article is available as a PDF (126.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becx M. C., Janssen A. J., Clasener H. A., de Koning R. W. Metronidazole-resistant Helicobacter pylori. Lancet. 1990 Mar 3;335(8688):539–540. doi: 10.1016/0140-6736(90)90772-w. [DOI] [PubMed] [Google Scholar]
  2. Bell G. D., Bate C. M., Axon A. T., Tildesley G., Kerr G. D., Green J. R., Emmas C. E., Taylor M. D. Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial. Aliment Pharmacol Ther. 1995 Oct;9(5):513–520. doi: 10.1111/j.1365-2036.1995.tb00414.x. [DOI] [PubMed] [Google Scholar]
  3. Blaser M. J., Parsonnet J. Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest. 1994 Jul;94(1):4–8. doi: 10.1172/JCI117336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Borody T. J., Cole P., Noonan S., Morgan A., Lenne J., Hyland L., Brandl S., Borody E. G., George L. L. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust. 1989 Oct 16;151(8):431–435. doi: 10.5694/j.1326-5377.1989.tb101251.x. [DOI] [PubMed] [Google Scholar]
  5. Edwards D. I. Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother. 1993 Jan;31(1):9–20. doi: 10.1093/jac/31.1.9. [DOI] [PubMed] [Google Scholar]
  6. Edwards D. I. Nitroimidazole drugs--action and resistance mechanisms. II. Mechanisms of resistance. J Antimicrob Chemother. 1993 Feb;31(2):201–210. doi: 10.1093/jac/31.2.201. [DOI] [PubMed] [Google Scholar]
  7. Glupczynski Y., Burette A., De Koster E., Nyst J. F., Deltenre M., Cadranel S., Bourdeaux L., De Vos D. Metronidazole resistance in Helicobacter pylori. Lancet. 1990 Apr 21;335(8695):976–977. doi: 10.1016/0140-6736(90)91043-a. [DOI] [PubMed] [Google Scholar]
  8. Goddard A. F., Logan R. P. Antimicrobial resistance and Helicobacter pylori. J Antimicrob Chemother. 1996 Apr;37(4):639–643. doi: 10.1093/jac/37.4.639. [DOI] [PubMed] [Google Scholar]
  9. Goodwin C. S., Marshall B. J., Blincow E. D., Wilson D. H., Blackbourn S., Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol. 1988 Feb;41(2):207–210. doi: 10.1136/jcp.41.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Graham D. Y. A reliable cure for Helicobacter pylori infection? Gut. 1995 Jul;37(1):154–156. doi: 10.1136/gut.37.1.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Graham D. Y. Campylobacter pylori and peptic ulcer disease. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):615–625. doi: 10.1016/s0016-5085(89)80057-5. [DOI] [PubMed] [Google Scholar]
  12. Graham D. Y., de Boer W. A., Tytgat G. N. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol. 1996 Jun;91(6):1072–1076. [PubMed] [Google Scholar]
  13. Haas C. E., Nix D. E., Schentag J. J. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother. 1990 Sep;34(9):1637–1641. doi: 10.1128/aac.34.9.1637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Johnson P. J. Metronidazole and drug resistance. Parasitol Today. 1993 May;9(5):183–186. doi: 10.1016/0169-4758(93)90143-4. [DOI] [PubMed] [Google Scholar]
  15. Karita M., Kouchiyama T., Okita K., Nakazawa T. New small animal model for human gastric Helicobacter pylori infection: success in both nude and euthymic mice. Am J Gastroenterol. 1991 Nov;86(11):1596–1603. [PubMed] [Google Scholar]
  16. Karita M., Li Q., Cantero D., Okita K. Establishment of a small animal model for human Helicobacter pylori infection using germ-free mouse. Am J Gastroenterol. 1994 Feb;89(2):208–213. [PubMed] [Google Scholar]
  17. Karita M., Li Q., Okita K. Evaluation of new therapy for eradication of H. pylori infection in nude mouse model. Am J Gastroenterol. 1993 Sep;88(9):1366–1372. [PubMed] [Google Scholar]
  18. Krakowka S., Morgan D. R., Kraft W. G., Leunk R. D. Establishment of gastric Campylobacter pylori infection in the neonatal gnotobiotic piglet. Infect Immun. 1987 Nov;55(11):2789–2796. doi: 10.1128/iai.55.11.2789-2796.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Logan R. P., Gummett P. A., Misiewicz J. J., Karim Q. N., Walker M. M., Baron J. H. One week eradication regimen for Helicobacter pylori. Lancet. 1991 Nov 16;338(8777):1249–1252. doi: 10.1016/0140-6736(91)92111-e. [DOI] [PubMed] [Google Scholar]
  20. Marchetti M., Aricò B., Burroni D., Figura N., Rappuoli R., Ghiara P. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science. 1995 Mar 17;267(5204):1655–1658. doi: 10.1126/science.7886456. [DOI] [PubMed] [Google Scholar]
  21. Matsumoto S., Washizuka Y., Matsumoto Y., Tawara S., Ikeda F., Yokota Y., Karita M. Induction of ulceration and severe gastritis in Mongolian gerbil by Helicobacter pylori infection. J Med Microbiol. 1997 May;46(5):391–397. doi: 10.1099/00222615-46-5-391. [DOI] [PubMed] [Google Scholar]
  22. Meingassner J. G., Thurner J. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother. 1979 Feb;15(2):254–257. doi: 10.1128/aac.15.2.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. O'Riordan T., Mathai E., Tobin E., McKenna D., Keane C., Sweeney E., O'Morain C. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut. 1990 Sep;31(9):999–1002. doi: 10.1136/gut.31.9.999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rautelin H., Seppälä K., Renkonen O. V., Vainio U., Kosunen T. U. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother. 1992 Jan;36(1):163–166. doi: 10.1128/aac.36.1.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Shuto R., Fujioka T., Kubota T., Nasu M. Experimental gastritis induced by Helicobacter pylori in Japanese monkeys. Infect Immun. 1993 Mar;61(3):933–939. doi: 10.1128/iai.61.3.933-939.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tytgat G. N. No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease. Aliment Pharmacol Ther. 1995;9 (Suppl 1):39–42. doi: 10.1111/j.1365-2036.1995.tb00782.x. [DOI] [PubMed] [Google Scholar]
  27. van Zwet A. A., Thijs J. C., Schievink-de Vries W., Schiphuis J., Snijder J. A. In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori. Antimicrob Agents Chemother. 1994 Feb;38(2):360–362. doi: 10.1128/aac.38.2.360. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES